Chloragard® Technology is designed to reduce microbial colonization of pathogens responsible for causing central line–associated bloodstream infections (CLABSIs). Proven 99.99% colonization reduction against gram-positive and gram-negative bacteria and fungi, including pathogens such as MRSA, VRE, Escherichia coli, Candida albicans, and Acinetobacter baumannii for at least 30 days7
Chlorag+ard® Technology provides an antithrombogenic effect on catheter surfaces due to the chlorhexidine coating eluting slowly over time. Chlorag+ard® Technology reduces thrombus accumulation on catheter surfaces due to thrombin inhibition by chlorhexidine. Inhibition of thrombin does not allow the final step of the common-pathway-the conversion of soluble Fibrinogen to Fibrin clot. An in vivo study has shown a 61% reduction in thrombus accumulation on catheter surfaces after 30 days.8 When challenged with infection, an in vivo study has shown a 92% reduction in thrombus accumulation on catheter surfaces after 30 days.9 In vitro tests have shown reduction in intraluminal thrombotic occlusion as evidenced by 51% less pressure to clear thrombus.10
In an in vivo study, Chlorag+ard® Technology demonstrated luminal protection through 72% less intimal hyperplasia after 30 days and a reduction in phlebitis.
When developing ARROW® Products, our goal is to help make challenging procedures a little easier for you and a lot safer for both you and your patients. Our PICCs are no exception. The ARROW® PICCs is pressure-injectable, flexible and easy to use. Plus, it comes with five unique features that are specifically designed to help reduce complications and facilitate the procedure from pre-insertion setup to post-insertion maintenance. Packaged in our intuitive ARROW® ErgoPack® Maximal Barrier Tray, the ARROW® PICCs offers the following unique advantages.
Our PICCs have unique advantages to get you closer to zero learn more by browsing the ARROW® PICCs features.
Chlorag+ard® Technology is a powerful chlorhexidine-based treatment that provides antimicrobial and antithrombogenic benefits. Chlorag+ard® Technology can be a tool to help your institution attain and sustain the goal of zero by offering protection beyond insertion for at least 30 days.
Learn more at Chlorag+ard.com
Chlorag+ard® Technology provides powerful, continuous protection for at least 30 days.
Chlorag+ard® Technology releases an initial burst of chlorhexidine immediately after insertion to protect the subcutaneous tract. Subsequently, Chlorag+ard® continues to release for at least 30 day.
Chlorag+ard® is proven effective against pathogens responsible for healthcare-associated infections.
Ready for navigation the moment you open it.
Now, ARROW® PICCs can come pre-loaded with the ARROW® VPS® Stylet already in place. Our unique Vascular Positioning System® employs Doppler ultrasound and intravascular ECG along with advanced algorithms to guide you as the catheter tip advances through the vasculature. So when you achieve a steady Blue Bullseye symbol on the display, you’ll be sure you’ve arrived at the optimal location—the lower 1/3 of the SVC-CAJ. An innovation so remarkable, it achieves a greater than 98% success rate on first placement attempt when a steady Blue Bullseye is illuminated.6
Learn more about the ARROW® VPS® .
1 Collins JL, Lutz RJ. In Vitro Study of Simultaneous Infusion of Incompatible Drugs in Multilumen Catheters. Heart & Lung. 1991; 20(3):271-7.
2 Nifong TP and McDevitt TJ. The effect of catheter to vein ratio on blood flow rates in a simulated model of peripherally inserted central venous catheters. Chest 2011;140;48-53
3 Grove JR, Pevec WC. "Venous Thrombosis Related to Peripherally Inserted Central Catheters." Journal of Vascular and Interventional Radiology. 2000; 11: 837-840
4 Trerotola, S, Stavropoulos, S, Mondschein, J, et al. Triple-lumen peripherally inserted central catheter in patients in the critical care unit: prospective evaluation. Radiology 2010;256(1):312-330
5 In vitro data on file. Teleflex Incorporated
6 Clinical Data on File at VasoNova, Inc..
7 In vitro data on file. Teleflex Incorporated.
8 As compared to uncoated PICCs, intravascular ovine model.
9 As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus.
10 As compared to uncoated PICCs, in vitro model measuring flush pressure post exposure to human blood.
12 Hidron AI, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007, Infect Control Hosp Epidemiol 2008; 29:996-1011
13 Robenshtok E et al. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteremia: risk factors and outcomes. J Hosp Infect. 2006 Nov; 64(3): 282-7
14 Al-Hasan MN et al. Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998-2007. Clin Microbiol Infect. 2011 Apr; 17(4) 539-45
15 Laupland KB et al. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 2008;14:1041–1047
16 McKinnell JA et al. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect 2011 Sep;139(9):1342-50
17 Suppli M et al. Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect. 2011 Jul; 17(7):1078-83
18 Kojic E et al. Candida Infections of Medical Devices. Clin Micro Reviews, 2004;17:2: 255-267
19 Farr BM et et al. Catheter Related Infections 2nd Edition, Revised and Expanded. 2005;127(Ch 6), 467(Ch 18)
20 Byers K et al. Catheter-related infections in the critically ill. 2004;95(Ch 6)